EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?

Sydney Dubois iD, Richard Layese, Nicolas Limal, Laetitia Languille, Willy Kini-Matondo, Matthieu Mahevas iD, Marc Michel, Etienne Audureau, Bertrand Godeau iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Sydney Dubois und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitau…. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous immunoglobulin (IVIg) is the gold standard treatment for severe cases of immune thrombocytopenia (ITP). However, its cost, limited duration of efficacy and market supply tension have led French guidelines to reserve IVIg for ITP patients with formal contra‐indications to corticosteroids, with French bleeding score (‘Khellaf score’) > 8, and corticosteroid‐resistant patients either with Khellaf score ≤ 8 or in preparation for an invasive procedure or during pregnancy. We studied the prescribing practices of IVIg for ITP in real‐life conditions and assessed their compliance with French guidelines. A monocentric retrospective study was conducted between 2016 and 2020 among 114 patients hospitalized in our unit, for a total of 208 IVIg treatments. In 37% of cases, the Khellaf score was >8, validating IVIg prescription according to French guidelines. In the remaining cases, reasons noted for use of IVIg included corticosteroid resistance (33.7%), preparation for an invasive procedure (8.5%), context of pregnancy (6.6%) and contra‐indication to corticosteroids (3.3%). After analysis, IVIg prescription was considered valid according to current French guidelines in 84.4% of cases. Non‐compliant IVIg prescription was more frequent in younger patients ( p = 0.027). Concomitant anti‐coagulation was also noted as an argument for IVIg prescription outside of the current French guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousPurpura, Thrombocytopenic, IdiopathicHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedPregnancyAdrenal Cortex HormonesAged, 80 and overGuideline Adherence

Stichwörter der Autor:innen

immune thrombocytopeniaintravenous immunoglobulin

Substanzen

Immunoglobulins, IntravenousAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, Fran…
  • Department of Hematology, Centre Henri Becquerel, Rouen, France.
  • Université Paris-Est Créteil, INSERM, IMRB, Creteil, France.
  • Public Health Department & Clinical Research Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Creteil, France.
  • Pharmacy Department, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
  • Clinical Epidemiology and Ageing (CEpiA) Unit EA7376, Université Paris-Est Créteil (UPEC), Créteil, France.

ORCID-Profile: Sydney Dubois, Matthieu Mahevas, Bertrand Godeau

Zitieren

APA

Dubois, S., Layese, R., Limal, N., Languille, L., Kini-Matondo, W., Mahevas, M., Michel, M., Audureau, E., & Godeau, B. (2024). When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?. British Journal of Haematology. https://doi.org/10.1111/bjh.19817

Vancouver

Dubois S, Layese R, Limal N, Languille L, Kini-Matondo W, Mahevas M, et al. When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?. British Journal of Haematology. 2024. doi:10.1111/bjh.19817

BibTeX
@article{Dubois2024,
  author = {Dubois, Sydney and Layese, Richard and Limal, Nicolas and Languille, Laetitia and Kini-Matondo, Willy and Mahevas, Matthieu and Michel, Marc and Audureau, Etienne and Godeau, Bertrand},
  title = {When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19817}
}
Kostenlos starten →